Patient tumor burden and systemic inflammation were associated with liso-cel CAR T cell expansion, efficacy, and safety. In general, higher tumor burden was associated with higher in vivo CAR T cell expansion but lower efficacy and higher risk for adverse events. Higher systemic inflammation at baseline was associated with higher risk for adverse events. In the drug product, increased antigen-specific cytokine levels were positively associated with expansion and efficacy, and higher frequencies of less differentiated central memory CAR T cells were associated with higher expansion and efficacy. Taken together, the application of supervised learning techniques offers us novel insights into the combinational effects of response to liso-cel and identifies potential opportunities for future combination or manufacturing strategies to improve clinical response.]

————————————————————————————————————————————————————————